Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Blood biomarker changes following therapeutic hypothermia in ischemic stroke

  • Palà, Elena|||0000-0002-1074-990X
  • Penalba, Anna
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Lamana-Vallverdu, Marcel
  • Meisel, Christian
  • Meisel, Andreas
  • van der Worp, H. Bart
  • R Macleod, Malcolm
  • Kallmünzer, Bernd
  • Schwab, Stefan
  • Montaner, Joan|||0000-0003-4845-2279
Therapeutic hypothermia is a promising candidate for stroke treatment although its efficacy has not yet been demonstrated in patients. Changes in blood molecules could act as surrogate markers to evaluate the efficacy and safety of therapeutic cooling. Blood samples from 54 patients included in the EuroHYP-1 study (27 treated with hypothermia, and 27 controls) were obtained at baseline, 24 ± 2 h, and 72 ± 4 h. The levels of a panel of 27 biomarkers, including matrix metalloproteinases and cardiac and inflammatory markers, were measured. Metalloproteinase-3 (MMP-3), fatty-acid-binding protein (FABP), and interleukin-8 (IL-8) increased over time in relation to the hypothermia treatment. Statistically significant correlations between the minimum temperature achieved by each patient in the hypothermia group and the MMP-3 level measured at 72 h, FABP level measured at 24 h, and IL-8 levels measured at 24 and 72 h were found. No differential biomarker levels were observed in patients with poor or favorable outcomes according to modified Rankin Scale scores. Although the exact roles of MMP3, FABP, and IL-8 in hypothermia-treated stroke patients are not known, further exploration is needed to confirm their roles in brain ischemia. Changes in blood molecules could act as surrogate markers to evaluate the efficacy and safety of therapeutic cooling. After evaluating a panel of 27 biomarkers including matrix metalloproteinases, cardiac, and inflammatory markers in the blood of patients treated with hypothermia and controls, MMP-3, FABP, and IL-8 increased over time in relation to the hypothermia treatment. These proteins deserve further exploration to confirm their role in brain ischemia.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cold stress protein RBM3 responds to hypothermia and is associated with good stroke outcome

  • Ávila-Gómez, Paulo
  • Vieites-Prado, Alba
  • Dopico-López, Antonio
  • Bashir, Saima
  • Fernández-Susavila, Héctor
  • Gubern, Carme|||0000-0001-8378-4477
  • Pérez-Mato, María
  • Correa-Paz, Clara
  • Iglesias-Rey, Ramón|||0000-0002-9985-9135
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Wellmann, Sven
  • Montaner, Joan|||0000-0003-4845-2279
  • Serena, Joaquín|||0000-0002-4478-7744
  • Castillo, José
  • Hervella, Pablo|||0000-0003-1249-6333
  • Campos, Francisco|||0000-0001-8665-1039
RNA-binding motif protein 3 is a molecular marker of hypothermia that has proved neuroprotective in neurodegenerative disease models. However, its relationship to the well-recognized therapeutic effect of hypothermia in ischaemic stroke had not been studied. In this work, the expression of RNA-binding motif protein 3 was investigated in ischaemic animal models subjected to systemic and focal brain hypothermia, specifically the effects of RNA-binding motif protein 3 silencing and overexpression on ischaemic lesions. Moreover, the association of RNA-binding motif protein 3 levels with body temperature and clinical outcome was evaluated in two independent cohorts of acute ischaemic stroke patients (n = 215); these levels were also determined in a third cohort of 31 patients derived from the phase III EuroHYP-1 trial of therapeutic cooling in ischaemic stroke. The preclinical data confirmed the increase of brain RNA-binding motif protein 3 levels in ischaemic animals subjected to systemic and focal hypothermia; this increase was selectively higher in the cooled hemisphere of animals undergoing focal brain hypothermia, thus confirming the direct effect of hypothermia on RNA-binding motif protein 3 expression, while RNA-binding motif protein 3 up-regulation in ischaemic brain regions led to functional recovery. Clinically, patients with body temperature <37.5°C in the first two cohorts had higher RNA-binding motif protein 3 values at 24 h and good outcome at 3 months post-ischaemic stroke, while RNA-binding motif protein 3 levels in the cooled third cohort tended to exceed those in placebo-treated patients. These results make RNA-binding motif protein 3 a molecular marker associated with the effect of hypothermia in ischaemic stroke and suggest its potential application as a promising protective target. Hypothermia is an effective neuroprotective treatment in stroke. We have demonstrated that the expression of RBM3 is increased under hypothermia treatment in animal models of ischaemia and stroke patients. These results evidence the potential application of RBM3 as a promising protective target against ischaemia